AKEBIA THERAPEUTICS, INC. (AKBA) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 24.81M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 24.75M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 349.66M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $24.81M | $24.75M | (m) | (m) | $349.66M | (m) |
| 2026-03-31 | (m) | (m) | $12.49M | $36.40M | (m) | (m) | $362.52M | (m) |
| 2025-12-31 | (m) | (m) | (m) | $48.25M | (m) | (m) | $376.56M | (m) |
| 2025-09-30 | (m) | (m) | (m) | $47.64M | (m) | (m) | $364.15M | (m) |
| 2025-06-30 | (m) | (m) | (m) | $47.06M | (m) | (m) | $345.60M | (m) |
| 2025-03-31 | (m) | (m) | (m) | $46.51M | (m) | (m) | $310.19M | (m) |
| 2024-12-31 | (m) | (m) | $0.00 | $38.69M | (m) | (m) | $220.67M | (m) |
| 2024-09-30 | (m) | (m) | $0.00 | $38.35M | (m) | (m) | $207.14M | (m) |
| 2024-06-30 | (m) | (m) | $0.00 | $38.03M | (m) | (m) | $220.20M | (m) |
| 2024-03-31 | (m) | (m) | $0.00 | $30.14M | (m) | (m) | $225.48M | (m) |
| 2023-12-31 | (m) | (m) | $17.50M | $17.18M | (m) | (m) | $241.70M | (m) |
| 2023-09-30 | (m) | (m) | $8.00M | $34.61M | (m) | (m) | $235.00M | (m) |
| 2023-06-30 | (m) | (m) | $24.00M | $18.49M | (m) | (m) | $253.71M | (m) |
| 2023-03-31 | (m) | (m) | $24.00M | $26.30M | (m) | (m) | $276.86M | (m) |
| 2022-12-31 | (m) | (m) | $32.00M | $34.08M | (m) | (m) | $351.83M | (m) |
| 2022-09-30 | (m) | (m) | $65.95M | (m) | (m) | (m) | $435.89M | (m) |
| 2022-06-30 | (m) | (m) | $98.16M | (m) | (m) | (m) | $521.80M | (m) |
| 2022-03-31 | (m) | (m) | $97.85M | (m) | (m) | (m) | $535.36M | (m) |
| 2021-12-31 | (m) | (m) | $97.54M | $0.00 | (m) | (m) | $525.55M | (m) |
| 2021-09-30 | (m) | (m) | (m) | $97.23M | (m) | (m) | $602.27M | (m) |
| 2021-06-30 | (m) | (m) | (m) | $96.92M | (m) | (m) | $611.86M | (m) |
| 2021-03-31 | (m) | (m) | (m) | $96.61M | (m) | (m) | $628.70M | (m) |
| 2020-12-31 | (m) | (m) | (m) | $96.38M | (m) | (m) | $644.14M | (m) |
| 2020-09-30 | (m) | (m) | (m) | $76.61M | (m) | (m) | $676.14M | (m) |
| 2020-06-30 | (m) | (m) | (m) | $76.34M | (m) | (m) | $745.17M | (m) |
| 2020-03-31 | (m) | (m) | (m) | $76.07M | (m) | (m) | $787.72M | (m) |
| 2019-12-31 | (m) | (m) | (m) | $75.81M | (m) | $147.69M | $771.20M | (m) |
| 2018-12-31 | (m) | (m) | $15.00M | (m) | (m) | $321.39M | $996.54M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |